RankAlpha logo
Back to Rankings

ACHV

Achieve Life SciencesA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Post-earnings bulls can point to the large financing, explicit commercial-build steps, and management's statement that Adare transfer work is already advanced, which together reduce the chance that ACHV needs another near-term capital raise before the next major regulatory step.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.1.
What can break
ACHV remains effectively a single-asset, pre-revenue biotech, so any slippage in Adare transfer, validation, or NDA resubmission timing would likely pressure the equity disproportionately.
Momentum
93
Value
41
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $10.00 · Bear $3.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $14.00
Why
Momentum93 · Δ7d +1.1
Value41 · Δ7d +0.1
Sentiment66 · Δ7d -11.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
93
34% active weight
Current posture
7d trendImproving
Δ7d
+1.1
Δ21d
+4.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
66
33% active weight
Current posture
7d trendSoftening
Δ7d
-11.1
Δ21d
-
Why this grade

Composite grade A. Momentum 92.8 / Value 41.1 / Sentiment 65.9

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$544.09M
Beta
1.83
Shares Out
53.23M
P/E (TTM) · Derived
-8.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.73
Rev YoY
-
EPS YoY
+22.3%
Gross Margin
-
Op Margin
-
Net Debt
-$24.52M
Current Ratio
5.14
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology